Your browser is no longer supported. Please, upgrade your browser.
DXR Daxor Corporation monthly Stock Chart
Daxor Corporation
Index- P/E- EPS (ttm)-0.25 Insider Own4.60% Shs Outstand3.75M Perf Week-14.68%
Market Cap42.71M Forward P/E- EPS next Y- Insider Trans-31.61% Shs Float0.79M Perf Month192.05%
Income-1.20M PEG- EPS next Q- Inst Own3.50% Short Float0.01% Perf Quarter120.21%
Sales0.60M P/S71.19 EPS this Y-160.90% Inst Trans-2.96% Short Ratio0.00 Perf Half Y102.67%
Book/sh2.01 P/B5.67 EPS next Y- ROA-6.10% Target Price30.00 Perf Year19.79%
Cash/sh0.00 P/C- EPS next 5Y- ROE-8.30% 52W Range3.40 - 21.66 Perf YTD149.08%
Dividend0.03 P/FCF- EPS past 5Y-23.00% ROI1.40% 52W High-48.98% Beta0.53
Dividend %0.26% Quick Ratio- Sales past 5Y-25.50% Gross Margin64.80% 52W Low224.99% ATR1.94
Employees37 Current Ratio- Sales Q/Q-25.00% Oper. Margin58.60% RSI (14)66.87 Volatility20.89% 25.77%
OptionableNo Debt/Eq0.31 EPS Q/Q92.40% Profit Margin- Rel Volume0.19 Prev Close11.39
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume700.17K Price11.05
Recom- SMA2059.12% SMA50106.05% SMA20097.04% Volume58,564 Change-2.99%
Mar-22-18 09:00AM  Daxor to Exhibit at the American Association of Heart Failure Nurses 2018 Advanced Heart Failure Symposium GlobeNewswire
Mar-16-18 08:20AM  Todays Research Reports on Stocks to Watch: Daxor and Solid Biosciences ACCESSWIRE
Mar-15-18 02:00PM  Daxor, Analysis of the BVA-100 Updates, Financial Data, and Product Review ACCESSWIRE +71.16%
Mar-14-18 08:00AM  New Data Showing Patient Care Individualized by Daxors Precision Blood Volume Analysis Reduces Heart Failure Readmissions by 56% and Mortality by over 80% Presented at the American College of Cardiology 2018 Annual Scientific Session GlobeNewswire +56.00%
Mar-09-18 11:55AM  Daxor Corporation Announces Positive New Critical Care Research Highlighting Benefit from BVA Use; Daxor Corporation to Exhibit at the American College of Cardiology 2018 Annual Meeting (NYSE MKT LLC: DXR) GlobeNewswire -8.24%
Mar-08-18 12:56PM  Daxor Corporation Announces Rise in Kit Sales, New Device Sale, and Filing of Form N-CSR for 2017 (NYSE MKT LLC: DXR) GlobeNewswire +76.73%
Jan-23-18 03:53PM  Daxor Corporation (NYSEMKT:DXR): Time For A Financial Health Check Simply Wall St. -8.16%
Dec-28-17 04:09PM  DAXOR CORPORATION REVISES 2017 DIVIDEND GlobeNewswire
10:47AM  Daxor Corp. : DXR-US: Dividend Analysis : December 21st, 2017 (record date) : By the numbers : December 28, 2017 Capital Cube
Dec-27-17 05:55PM  Did Daxor Corporations (NYSEMKT:DXR) Earnings Growth Outperform The Industry? Simply Wall St.
Nov-21-17 10:09AM  Daxor Corporation (DXR): Risks You Need To Consider Before Buying Simply Wall St. +7.95%
Nov-01-17 09:00AM  Daxor Corporation Announces Share Buyback Program GlobeNewswire
Sep-15-17 09:00AM  Daxor Corporation Forwarding Plans to Expand Impact at HFSA 2017 and Beyond Marketwired
Jun-29-17 02:44PM  Daxor Corporation Holds Annual Meeting, Provides Business Growth Update and Strategic Plan Marketwired -7.71%
May-31-17 09:00AM  Daxor Corporation Announces Hiring of Chief Financial Officer Marketwired
May-23-17 12:38PM  ETFs with exposure to Daxor Corp. : May 23, 2017 Capital Cube
May-03-17 03:51PM  ETFs with exposure to Daxor Corp. : May 3, 2017 Capital Cube
May-02-17 12:24PM  Daxor Corp. :DXR-US: Earnings Analysis: 2016 By the Numbers : May 2, 2017 Capital Cube
Apr-10-17 04:55PM  Daxor Corporation Announces Delay in Filing of Form N-CSR for December 31, 2016, and the Uniformed Services University of Health Sciences has been awarded a grant to study hemodilution utilizing Daxor's BVA-100 device Marketwired
Feb-16-17 12:53PM  DAXOR CORP Files SEC form 8-K, Change in Directors or Principal Officers
Feb-01-17 04:24PM  Daxor Corporation Announces Death of Founder, Chief Medical Officer, and Developer of Blood Volume Analysis and Inventor of the Daxor BVA-100 Device, Dr. Joseph Feldschuh Marketwired +5.27%
Jan-30-17 09:00AM  SCCM17 Randomized Controlled Trial Analysis: Individualized Volume Management Guided by Direct Blood Volume Analysis (BVA) Sharply Lowers Early ICU Mortality vs Pulmonary Artery Catheter Alone Marketwired
Jan-19-17 12:48PM  ETFs with exposure to Daxor Corp. : January 19, 2017 Capital Cube
12:48PM  ETFs with exposure to Daxor Corp. : January 19, 2017
Jan-15-17 10:10AM  Huge Michael Dell Purchase Highlights Insider Buying: Dell Technologies, Accelerate Diagnostics, Loxo Oncology and More 24/7 Wall St.
Nov-18-16 02:59PM  Daxor Corporation Announces Dividend, Patent Approval, Title Change Marketwired
Sep-29-16 08:30AM  Daxor Corporation Announces Two New Studies From the Mayo Clinic and Lankenau Medical Center Presented at Heart Failure Society of America 2016 Highlight Unique Ability of BVA to Identify High Risk at Discharge in Hospitalized Heart Failure Patients Marketwired
Sep-27-16 11:39AM  DAXOR CORP Files SEC form 8-K/A, Change in Directors or Principal Officers
09:18AM  Daxor Corp. :DXR-US: Earnings Analysis: For the six months ended June 30, 2016 : September 27, 2016 Capital Cube
09:18AM  Daxor Corp. :DXR-US: Earnings Analysis: For the six months ended June 30, 2016 : September 27, 2016
Sep-15-16 09:00AM  Daxor Corporation Announces Filing of Form N-CSR for June 30, 2016 Marketwired
Jul-27-16 09:00AM  In Heart Failure, One Size Does Not Fit All: New Mayo Clinic BVA Study Published in Journal of the American College of Cardiology-Heart Failure Highlights the Need for Individualized Decongestive Strategies Marketwired
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thompson SorenVice PresidentMar 15Sale19.542,95057,634950Mar 19 05:17 PM
Feldschuh Michael RichardPresidentMar 15Sale16.4020,800341,120152,806Mar 19 05:14 PM
Feldschuh Jonathan AdamDirectorMar 15Sale18.6319,194357,5843,908Mar 19 05:12 PM
FELDSCHUH JOSEPH10% OwnerMar 09Sale6.4437,000238,2802,774,455Mar 19 05:25 PM
Feldschuh Michael RichardPresident & CEOOct 17Buy4.6629172,799Oct 18 09:16 PM
Feldschuh Michael RichardPresident & CEOOct 16Buy4.95148733172,797Oct 18 09:16 PM
Feldschuh Michael RichardPresident & CEOOct 13Buy4.95315172,649Oct 18 09:16 PM
Feldschuh Michael RichardPresident & CEOOct 12Buy4.9549243172,646Oct 18 09:16 PM
Feldschuh Michael RichardPresident & CEOSep 05Buy5.40100540173,097Sep 12 04:02 PM